Thomson Reuters News & Insight
Featured Content from WESTLAW
Beginning in June, Thomson Reuters News & Insight content will be available exclusively on WestlawNext®, as part of its Practitioner Insights offering. On June 21, the Thomson Reuters News & Insight website, iPhone® app and newsletters will be discontinued. See Frequently Asked Questions to learn more.

Legal

  •  
  •  

Vitamins and supplements in a store. File 2003 REUTERS David Gray

Jury hears price-fixing claims vs Chinese vitamin C companies

2/26/2013 COMMENTS (0)

By Andrew Longstreth 

NEW YORK, Feb 26 (Reuters) - Two Chinese vitamin C manufacturers participated in a price-fixing conspiracy that "struck a blow to our free enterprise system," a lawyer told a jury in Brooklyn federal court on Monday.

The lawyer, William Isaacson of Boies, Schiller & Flexner, represents a class of vitamin C purchasers that accuses the Chinese companies of fixing prices over a period from December 2001 to June 2006. The plaintiffs, which are led by a small New Jersey distributor called The Ranis Company Inc, are seeking $54 million, which could be tripled under antitrust law.

Isaacson told the nine-member jury that the Chinese manufacturers, concerned about falling vitamin C prices, came to an agreement in 2001 to limit production in an effort to stabilize prices. He promised the jury that over the course of the trial, it would see internal company documents, including meeting minutes, proving a conspiracy.

"These companies met, agreed and conspired to increase prices in the U.S., contrary to our free enterprise system," Isaacson said. "We paid higher prices as a result."

Throughout his opening statement, Isaacson said the conduct at issue in the case was akin to the owners of gas stations getting together and agreeing on a price to charge customers.

Antitrust class actions rarely go to trial and this one is the first to involve Chinese corporate defendants, according to lawyers involved in the case.

The case also features a seldom used defense. The Chinese manufacturers, Hebei Welcome Pharmaceutical Co Ltd and Weisheng Pharmaceutical Co Ltd, argue that the Chinese government compelled them to coordinate their prices and production.

The so-called foreign compulsion doctrine protects defendants who are compelled by their own government to break U.S. law.

Daniel Mason of Zelle Hofmann Voelbel & Mason, who represents Weisheng, told the jury on Monday that the trial was "historic" and "unprecedented." Mason said that for the first time, a former Chinese government official would testify in a U.S. courtroom. That official, Mason said, is the "person who compelled the conduct in this case."

Mason counseled the jury that the Chinese government has different views about competition than the U.S. government. The Chinese government decided that vitamin C was a critical industry and made sure that the companies cooperated on price and production.

If the companies failed to heed the government's orders, Mason said they were subject to penalties such as export limits.

"They're not gas stations in Brooklyn," Mason said.

The case is In re: Vitamin C Antitrust Litigation, U.S. District Court for the Eastern District of New York, No. 06-md-1738.

For plaintiffs: William Isaacson of Boies, Schiller & Flexner.

For Weisheng: Daniel Mason of Zelle Hofmann Voelbel & Mason.

For Hebei: Charles Critchlow of Baker & McKenzie.

Follow us on Twitter @ReutersLegal | Like us on Facebook   


Register or log in to comment.

© 2013 Thomson Reuters